Oramed Pharmaceuticals Inc.
ORMP· Nasdaq
ORMPOramed Pharmaceuticals Inc.
Filed Jul 12, 2012 · 10-Q · 42 days after period end · 0001178913-12-001916
| Metric | Q3 2012 | Q3 2011 |
|---|---|---|
| Net Income | -$550.37K | $457.37K |
| EPS Diluted | $0.09 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
ended May 31, 2012 · filed Jul 12, 2012 · 42 d after period end
